Zaki Randa Mohammed, Alfadhel Munerah, DevanathaDesikan Seshadri Vidya, Albagami Faisal, Alrobaian Majed, Tawati Salha M, Warsi Musarrat Husain, Almurshedi Alanood S
Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, P.O. Box 173, Al-Kharj 11942, Saudi Arabia.
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt.
Saudi Pharm J. 2023 Jan;31(1):135-146. doi: 10.1016/j.jsps.2022.11.012. Epub 2022 Nov 23.
The present study was aimed to formulate and evaluate fast dissolving oral film of Rosuvastatin calcium to improve its bioavailability in comparison to typical solid oral dosage forms. The drug was formulated as solid dispersion with hydrophilic polymers and assessed for different constraints such as drug content, saturated solubility, and drug-polymer interaction. Best formula was selected and prepared in the form of orodispersible film. The films were developed by solvent casting method and examined for weight variations, drug content, folding endurance, pH, swelling profile, disintegration time, and dissolution. Further pharmacokinetic study was also performed on rabbit and compared with that of the marketed oral formulation. The drug and the polymers were found to be compatible with each other by FTIR study. Maximum solubility was found at drug polymer ratio of 1:4 and that was 54.53 ± 2.05 µg/mL. The disintegration time of the developed film was observed to be 10 ± 2.01 s, while release of the Rosuvastatin from the film was found to be 99.06 ± 0.40 in 10 min. Stability study shown that developed film was stable for three months. Further pharmacokinetic study revealed that developed orodispersible film had enhance oral bioavailability as compared to marketed product (Crestor® tablets). Conclusively, the study backs the development of a viable ODF of Rosuvastatin with better bioavailability.
本研究旨在制备并评估瑞舒伐他汀钙速溶口腔膜,以提高其生物利用度,并与典型的固体口服剂型进行比较。该药物被制成与亲水性聚合物的固体分散体,并针对不同的限制因素进行评估,如药物含量、饱和溶解度和药物-聚合物相互作用。选择最佳配方并制成口腔崩解膜形式。通过溶剂浇铸法制备薄膜,并检查其重量变化、药物含量、耐折性、pH值、溶胀曲线、崩解时间和溶出度。还对兔子进行了进一步的药代动力学研究,并与市售口服制剂进行了比较。通过傅里叶变换红外光谱(FTIR)研究发现药物和聚合物相互兼容。在药物与聚合物比例为1:4时发现最大溶解度,为54.53±2.05μg/mL。观察到所制备薄膜的崩解时间为10±2.01秒,而瑞舒伐他汀在10分钟内从薄膜中的释放率为99.06±0.40。稳定性研究表明所制备的薄膜在三个月内稳定。进一步的药代动力学研究表明,与市售产品(可定®片剂)相比,所制备的口腔崩解膜具有更高的口服生物利用度。总之,该研究支持开发一种具有更好生物利用度的可行的瑞舒伐他汀口腔崩解膜。